Sutent Sales in Small-Molecule Cancer Therapies Segment to Reach USD 2.50 Billion in 2023, Forecasts Visiongain

14 Jan 2013 • by Natalie Aster

In May 2010, Mylan Pharmaceuticals reportedly filed an abbreviated new drug application with the FDA seeking approval to market a generic form of Sutent and challenging on various grounds the Sutent basic patent, which expires in 2021, and two other patents, which expire in 2020 and 2021.

In June 2010, Pfizer filed a suit against Mylan Pharmaceuticals in the US district court for the district of Delaware asserting the infringement of those three patents; it is reported. In 2011 sales of the drug were $1.19bn. Sutent became a blockbuster in 2010, when sales of the drug reached $1.07bn, up from $0.96bn in 2009, an increase of 11%.

According to the report “Small-Molecule Targeted Cancer Therapies: World Market 2013-2023” by Visiongain, the Sutent’s sales in this segment will continue to grow strongly over the forecast period. Sales will reach $1.78bn in 2016. This growth represents a CAGR of 8.4% from 2011 to 2016.

Report Details:

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023
Published: December, 2012
Pages: 174
Price: US$ 2,497.00

From 2017 to 2023 Sutent’s sales in the small-molecule cancer therapies segment are set to continue their growth at a CAGR of 4.7%. The sales will reach $1.90bn in 2017, increasing to $2.22bn in 2020, and reaching $2.50bn in 2023. This represents an overall CAGR of 6.4% from 2011 to 2023.

More information can be found in the report “Small-Molecule Targeted Cancer Therapies: World Market 2013-2023” by Visiongain.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970